In vitro effects of antivascular endothelial growth factors on cultured human trabecular meshwork cells

Journal of Glaucoma

Volumn 19, Issue 7, 2010, Pages 437-441

  Kahook, Malik Y ^a   Ammar, David A ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

antiproliferative; bevacizumab; metabolic inhibitor; ranibizumab; trabecular meshwork; vascular endothelial growth factor

Indexed keywords

BEVACIZUMAB; BROXURIDINE; RANIBIZUMAB; TETRAZOLIUM; VASCULOTROPIN;

ARTICLE; CELL METABOLISM; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; DRUG INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; INTRAOCULAR PRESSURE; PRIORITY JOURNAL; TRABECULAR MESHWORK;

AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; CELL PROLIFERATION; CELL SEPARATION; CELLS, CULTURED; HUMANS; IMMUNOGLOBULIN FRAGMENTS; MIDDLE AGED; TRABECULAR MESHWORK; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77956058023     PISSN: 10570829     EISSN: None     Source Type: Journal    
DOI: 10.1097/IJG.0b013e3181ca74de     Document Type: Article

References (21)

1. Kourlas H, Abrams P. Ranibizumab for the treatment of neovascular age-related macular degeneration: a review. Clin Ther. 2007;29:1850-1861.
2. Avery RL, Pieramici DJ, Rabena MD, et al. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology. 2006;113:363-372.
3. Rich RM, Rosenfeld PJ, Puliafito CA, et al. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina. 2006;26:495-511.
4. Kahook MY, Schuman JS, Noecker RJ. Needle bleb revision of encapsulated filtering bleb with bevacizumab. Ophthalmic Surg Lasers Imaging. 2006;37:148-150.
5. Kahook MY, Schuman JS, Noecker RJ. Intravitreal bevacizumab in a patient with neovascular glaucoma. Ophthalmic Surg Lasers Imaging. 2006;37:144-146.
6. Kapetansky FM, Pappa KS, Krasnow MA, et al. Subconjunctival injection (s) of bevacizumab for failing filtering blebs. Invest Ophthalmol Vis Sci. 2007;48. ARVO E-Abstract 837.
7. Luthra S, Narayanan R, Marques LE, et al. Evaluation of in vitro effects of bevacizumab (Avastin) on retinal pigment epithelial, neurosensory retinal, and microvascular endothelial cells. Retina. 2006;26:512-518.
8. Spitzer MS, Wallenfels-Thilo B, Sierra A, et al. Antiproliferative and cytotoxic properties of bevacizumab on different ocular cells. Br J Ophthalmol. 2006;90:1316-1321.
9. Yoeruek E, Spitzer MS, Tatar O, et al. Safety profile of bevacizumab on cultured human corneal cells. Cornea. 2007;26:977-982.
10. ™) treated corneal stromal fibroblasts. Invest Ophthalmol Vis Sci. 2006;46. ARVO E-Abstract 1642.
11. Kernt M, Welge-Lussen U, Yu A, et al. Bevacizumab is not toxic to human anterior and posterior-segment cultured cells. Ophthalmologe. 2007;104:965-971.
12. Qin Q, Van Bergen N, Liew D, et al. Anti-VEGF treatment on human tenons' fibroblasts scarring activity in vitro. Invest Ophthalmol Vis Sci. 2008;49. ARVO E-Abstract 4541.
13. Kernt M, Neubauer AS, Kampik A, et al. Intravitreal bevacizumab (Avastin) treatment is safe in terms of intraocular and blood pressure. Acta Ophthalmol Scand. 2007;85:119-120. (Pubitemid 46140172)
14. Jalil A, Fenerty C, Charles S. Intravitreal bevacizumab (Avastin) causing acute glaucoma: an unreported complication. Eye. 2007;21:1541.
15. Bakri SJ, McCannel CA, Edwards AO, et al. Persistent ocular hypertension following intravitreal ranibizumab. Graefes Arch Clin Exp Ophthalmol. 2008;246:955-958.
16. Kahook MY, Kimura AE, Wong LJ, et al. Sustained elevation in intraocular pressure associated with intravitreal bevacizumab injections. Ophthalmic Surg Lasers Imaging. 2009;40:293-295.
17. Grisanti S, Biester S, Peters S, et al. Intracameral bevacizumab for iris rubeosis. Am J Ophthalmol. 2006;142:158-160.
18. Chalam KV, Gupta SK, Grover S, et al. Intracameral Avastin dramatically resolves iris neovascularization and reverses neovascular glaucoma. Eur J Ophthalmol. 2008;18:255-262.
19. Parnigotto PP, Bassani V, Montesi F, et al. Bovine corneal stroma and epithelium reconstructed in vitro: characterisation and response to surfactants. Eye. 1998;12:304-310.
20. Tripathi RC, Borisuth NS, Tripathi BJ. Mapping of Fc gamma receptors in the human and porcine eye. Exp Eye Res. 1991;53:647-656.
21. Zhu Q, Ziemssen F, Henke-Fahle S, et al. Vitreous levels of bevacizumab and vascular endothelial growth Factor-A in patients with choroidal neovascularization. Ophthalmology. 2008;115:1750-1755.